- Company
- Impinzi's indication of biliary tract cancer
- by Nov 16, 2022 06:10am
- AstraZeneca Korea announced on the 14th that its immune anticancer drug "Imfinzi" has received additional approval from the Ministry of Food and Drug Safety for biliary tract cancer. Imfinzi can be used as a combination therapy with Gemcitabine and Cisplatin in the primary treatment of patients with locally advanced or metastatic biliary t
- Company
- Tecentriq approved as adjuvant treatment for NSCLC
- by Nov 15, 2022 05:38am
- On the 14th, Roche Korea announced that its anti-PD-L1 immuno-oncology drug Tecentriq (atezolizumab) was approved as adjuvant therapy following resection in patients with early-stage non-small-cell-lung cancer, and became the first immunotherapy to receive approval for the indication. Tecentriq may now be used as an adjuvant treatment fol
- Company
- CR of AML new drug candidates is identified in Phase 1/2
- by Kim, Jin-Gu Nov 15, 2022 05:38am
- Hanmi Pharmaceutical announced on the 14th that it has confirmed cases of complete response (CR) in various dose groups as a result of phase 1/2 clinical trials of Tuspetinib (HM43239), which is being developed as an AML treatment. Aptose was recently introduced at the KOL webinar, "As a result of the global phase 1/2 for patients with recurr
- Company
- Merck KGaA has appointed Christoph Hamann
- by Nov 15, 2022 05:38am
- Merck Biopharma Korea announced on the 10th that it has appointed Christoph Hamann as the new general representative of its business unit. Harman served as general manager of Merck Biopharma in Malaysia, Singapore, and Brunei, and as Managing Director in Malaysia. Since joining Merck in 2009, he has built various careers through strategic and
- Company
- Adding AUS as a drug price reference country raise concerns
- by Nho, Byung Chul Nov 14, 2022 06:07am
- The health authorities are known to be considering including Canada and Australia as reference countries for drug pricing reevaluations. Currently, the Ministry of Health and Welfare, Health Insurance Review and Assessment Service, and the National Health Insurance Service refer to drug prices of G7 countries - US, UK, Germany, Switz
- Company
- Heart failure drug Entresto makes KRW 10 bil in Q3
- by Kim, Jin-Gu Nov 14, 2022 06:07am
- Novartis’ chronic heart failure treatment ‘Entresto’ is growing rapidly. Its quarterly sales first exceeded KRW 10 billion in 5 years since its release in Q3 this year. The analysis is that its rapid growth was due to its de facto domination of the market. However, with the nearing entry of ▲SGLT-2 class diabetes treatments, ▲new
- Company
- The market is recovering for the first time in two years
- by Kim, Jin-Gu Nov 14, 2022 06:07am
- The size of outpatient prescriptions of Montelukast for asthma and allergic rhinitis has increased by 21% in a year. The market, which had been stagnant for the past two years due to the COVID-19 incident and side effect issues, seems to be recovering from its previous year's prescription performance this year. It was found that the impurity neg
- Company
- The popular Daewoong's Nabota
- by Nov 14, 2022 06:06am
- Daewoong Pharmaceutical's botulinum toxin drug Nabota exceeded $100 million in cumulative sales in North America this year. This is an increase of 61% compared to the previous year. According to the earnings report of Daewoong Pharmaceutical partner Evolus on the 9th (local time), Jeuveau, which is sold by the company, recorded cumulative sal
- Company
- Daewoong obtained an item license for Fexuclu
- by Nov 11, 2022 05:52am
- Daewoong Pharmaceutical announced on the 10th that Fexuclu, a new drug for gastroesophageal reflux disease, obtained an item license from the Philippines FDA on the 3rd. The approval was made about eight months after submitting an application for item permission (NDA) at the end of February. It takes about three years to obtain an item licens
- Company
- SK Biopharm’s Q3 sales rise 270% with rise in Xcopri sales
- by Nov 11, 2022 05:51am
- SK Biopharmaceutical’s sales rose greatly in Q3 with the rising sales of its new anti-epileptic drug ‘Xcopri (cenobamate)’ in the US. On the 10th, SK Biopharmaceutical announced sales of KRW 88.8 billion in Q3 this year, a 270.9% on-year increase. The company also reported an operating loss of KRW 9.2 billion in the same period. A
